Elkady O.A.; Tadros M.I.; El-laithy H.M.
(Springer, 2020)
Risedronate sodium (RS) is a potent inhibitor of bone resorption, having an extreme poor permeability and limited oral bioavailability (0.62%). RS should be orally administered under fasting conditions while keeping in an ...